$BEAM News

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT

Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative

Beam sues 2 biotechs, alleging theft of base editing trade secrets

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock

Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows

Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow

Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) Congress - Slideshow

Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb